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Abstract
Hepatocyte nuclear factor 4α (HNF4α) is a nuclear receptor involved in glucose homeostasis and
is required for normal β cell function. Mutations in the HNF4α gene are associated with maturity
onset diabetes of the young type 1 (MODY1). The aim of the present study was to determine the
prevalence and nature of mutations in HNF4α gene in Iranian patients with a clinical diagnosis of
MODY and their family members. Twelve families including 30 patients with clinically MODY
diagnosis and 21 members of their family were examined using PCR-RFLP method and in case of
mutation confirmed by sequencing techniques. Fifty age and sex matched subjects with normal
fasting blood sugar (FBS) and Glucose tolerance test (GTT) were constituted the control group
and investigated in the similar pattern. Single mutation of V255M in the HNF4α gene was detected.
This known mutation was found in 8 of 30 patients and 3 of 21 individuals in relatives. Fifty healthy
control subjects did not show any mutation. Here, it is indicated that the prevalence of HNF4α
mutation among Iranian patients with clinical MODY is considerable. This mutation was present in
26.6% of our patients, but nothing was found in control group. In the family members, 3 subjects
with the age of ≤25 years old carried this mutation. Therefore, holding this mutation in this range
of age could be a predisposing factor for developing diabetes in future.
Background
Maturity onset diabetes of the young (MODY) is a geneti-
cally, metabolically, and clinically heterogeneous subtype
of diabetes mellitus characterized by early onset auto-
somal dominant inheritance and beta cell dysfunction
[1]. This monogenic disease accounts for 1-5% of all type
2 diabetes (T2D) cases and is characterized by high pene-
trance, early age at onset (usually before 25 years and
often in adolescence or childhood), primary defect in
insulin secretion, and mild to severe clinical manifesta-
tions [2]. Variants in six genes responsible for MODY have
been identified: hepatocyte nuclear factor 4α (HNF4α/
Published: 10 December 2009
Cardiovascular Diabetology 2009, 8:63 doi:10.1186/1475-2840-8-63
Received: 7 September 2009
Accepted: 10 December 2009
This article is available from: http://www.cardiab.com/content/8/1/63
© 2009 Taghavi et al; licensee BioMed Central Ltd. 
This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), 
which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.Cardiovascular Diabetology 2009, 8:63 http://www.cardiab.com/content/8/1/63
Page 2 of 6
(page number not for citation purposes)
MODY1; MIM#600281) on chromosome 20q [3], glu-
cokinase (GCK/MODY2; MIM#138079) on chromosome
7p [4], transcription factor 1 (TCF1/MODY3; MIM#
142410) on chromosome 12q [5], insulin promoter fac-
tor 1 (IPF1/MODY4; MIM#600733) on chromosome 13q
[6], transcription factor 2 (TCF2/MODY5; MIM#189907)
on chromosome 17q [7] and neurogenic differentiation
factor 1 (NEUROD1/MODY6; MIM#601724) on chro-
mosome 2q [8]. All of these genes encode proteins
involved in the glucose homeostasis of the pancreatic β
cell [9]. Heterozygous mutations in these genes appear to
result in different clinical presentations. The recent identi-
fication of these MODY genes currently allows investiga-
tion of the specific defects present in each family and
identification of the respective genotype-phenotype corre-
lations [2]. Exact relative prevalence of distinct MODY
subtypes is unknown and varies substantially in different
populations [10-12]. Additionally, in several populations
other yet unknown genes, known as MODY X may be
responsible for up to 79% of MODY cases [13]. This find-
ing suggests that additional MODY genes are likely to
exist.
Hepatocyte nuclear factor 4α is a member of the steroid/
thyroid hormone receptor super family and is expressed
in the liver, kidney, small intestine and pancreatic islets
[14,15]. It activates a wide variety of essential genes,
including those involved in cholesterol, fatty acid and glu-
cose metabolism and in liver differentiation [16]. The
MODY1 phenotype is because of a loss of HNF4α func-
tion [17]. The molecular mechanisms by which cause
mutations in HNF4α are not fully understood. Clinical
studies suggest that MODY1 is characterized by a defect in
glucose-stimulated insulin secretion, suggesting that
abnormal gene expression in the pancreatic β cell is
responsible for this disorder [18]. So, HNF4α is critical for
regulating glucose transport and glycolysis and in doing is
crucial for maintaining glucose homeostasis. Some mis-
sense mutations in the HNF4α gene have been shown to
segregate with diabetes in MODY pedigrees in different
populations.
The present study was undertaken to examine the preva-
lence and the nature of mutations in the HNF4α gene in a
group of Iranian MODY patients and their family mem-
bers, because identification of these mutations allowed
for presymptomatic diagnosis in the younger generations
and will improve medical follow up of the predisposed
individuals. Diagnosis of MODY has important implica-
tions for clinical management.
Subjects and Methods
Thirty patients with clinical feature of MODY were
included in this study. The screening criteria we used were:
1) patient and at least one first degree relative with T2D
diagnosed before 25 years of age, 2) laboratory approved
hyperglycemia and clinical manifestations of diabetes, 3)
positive family history for diabetes at least in two previous
generations, and 4) entering the disease into the family on
only one side. Patients with classic type 1 diabetes (acute
ketotic presentation or continuous requirement of insulin
within the first year of diagnosis) were excluded. Our
patients were recruited from Endocrinology Clinic of
Ghaem University Hospital in Mashhad, covering the gen-
eral population of this city. The patients' families were
screened further regarding the occurrence of T2D. Then
they were asked to participate in our study. Fifty age and
sex matched subjects which counted toward our control
group were evaluated by FBS and GTT not to miss any
undiagnosed diabetes.
This study was approved by ethics committee of Mashhad
University of Medical Sciences. Written informed consent
forms were filled for all the patients.
In the first part of the study, a medical questionnaire was
filled for every patient including demographic data, the
type of diabetes, duration of the disease, type of therapy
whether to use insulin or oral hypoglycemic agents, dura-
tion and current dose of drug usage. Correspondently,
height, weight and BMI were measured. Also information
on the medical history of individual family members was
obtained by another questionnaire.
In the latter step, blood samples were taken from the
patients and their nominated relatives for DNA extraction
and measurement of biochemical indices. Fasting plasma
glucose, fasting serum insulin, and hemoglobin A1C were
determined in all patients. Laboratory analyses were per-
formed with commercially available standardized meth-
ods.
For screening of the mutations, genomic DNA was iso-
lated from peripheral blood lymphocytes of patients and
relatives by salting out method [19]. PCR- RFLP was car-
ried out in all subjects took part in the study and addi-
tional process of sequencing was done in those cases in
which a mutation was detected by PCR. The eleven exons
and flanking introns in addition to Val/Met255 variant
were amplified. Specific primer sequences are described in
table 1. Our PCR mixture includes 200 ng of DNA, 10
pmoles of each primer, 200 μm dNTPs, 1.5 mM MgCl2
and Taq DNA polymerase (0.5 U/20 μl). The program of
thermal cycler was 5 min denaturation at 94°C followed
by 38 cycle of denaturation at 94°C for 1 min, annealing
at Tanneal (Table 1) for 1 min, and extension at 72°C for 1
min, with a final extension at 72°C for 5 min. Amplified
restricted fragments were detected after digestion withCardiovascular Diabetology 2009, 8:63 http://www.cardiab.com/content/8/1/63
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Table 1: Nucleotide sequences of DNA primers used for PCR amplification of the HNF4α gene
Region Sense primer (5'→3') Antisense primer (5'→3') Segment size Tannealing/°C
1 tgtaaaacgacggccagtgggcactgggaggaggcagt caggaaacagctatgacccttggcaacacctgtgctggc 405 bp 75
1b tgtaaaacgacggccagttcatatcagcaacatgtccg caggaaacagctatgaccgggctcttccctccagga 210 bp 73
2 tgtaaaacgacggccagtcttcctgaagcctcactcc caggaaacagctatgacccccaagtgtgcccatttcc 352 bp 75
3 tgtaaaacgacggccagtgttgtgtcttctccatcca caggaaacagctatgaccgcaggtggggcagtggtg 215 bp 56
4 tgtaaaacgacggccagttctccctcctcacctctctg caggaaacagctatgacccctctgtagtgtggggga 226 bp 56
5 tgtaaaacgacggccagtatctccagcattttcttccc caggaaacagctatgacccactgcccactactgccc 267 bp 72
6 tgtaaaacgacggccagtagggtacagatggcaaacac caggaaacagctatgaccaccctccctggagccctg 204 bp 70
7 tgtaaaacgacggccagttgacttcccatcctccctcc caggaaacagctatgaccggagagagagtcagggatgg 268 bp 68
8 tgtaaaacgacggccagtagctggaccctgctgccc caggaaacagctatgacccactccaaccccgcccct 354 bp 74
9 tgtaaaacgacggccagtgcatcccagactctccatcc caggaaacagctatgaccttgcaaggtaaaatcccagag 262 bp 72
10 tgtaaaacgacggccagtagcccctgtctgtctgtttg caggaaacagctatgaccgggactggtcctggcatcac 316 bp 72
Val/Met255 variant ccggagctggcggagatgacccg caggaaacagctatgaccggagagagagtcagggatgg 180 bp 70
Table 2: Characteristics of examined families
Family Number (Total Members) Affected Subjects Mean Age at Diagnosis (range)
1(2) 2 19(14-24)
2(3) 2 27(26-28)
3(7) 2 23.5(23-24)
4(5) 2 22(18-26)
5(6) 3 33(21-23)
6(5) 3 24(12-19)
7(6) 3 31.5(18-24)
8(2) 2 22.5(20-25)
9(2) 1 24
10(5) 4 50.5(21-33)
11(6) 4 52(23-30)
12(2) 2 24.5(24-25)Cardiovascular Diabetology 2009, 8:63 http://www.cardiab.com/content/8/1/63
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BstBI, and AvaI was only used for Val/Met255 variant. The
fragments were resolved on a 2% agarose gel and visual-
ized by staining with ethidium bromide. PCR products
were purified. For cycle sequencing, ABI (Applied Biosys-
tems) BigDye 3.1 chemistry was used. Sequencing runs
were performed on ABI 3730 sequencers with 50 cm cap-
illaries. Double stranded sequencing was performed in
cases we encountered difficulties in the interpretation.
Results
Clinical and Biochemical features
A total of 12 families with an autosomal dominant pat-
tern of occurrence of early onset diabetes were constituted
the cohort of the study. Table 2 summarizes characteristics
of the families. Most of the patients had an early onset of
diabetes (mean onset age of 24). Selected clinical charac-
teristics of the study subjects are demonstrated in table 3.
We had 22 women and 8 men in patients group and 10
women and 11 men in the family members group. For
comparison 50 sex and age matched healthy subjects were
selected as control group included 30 women and 20 men
with the range of age 25 to 35 years old. The diabetic
patients, at the time of the study, had a body mass index
(BMI) between 20 and 31 kg/m2. There was no significant
difference between the patients' BMI and other two
groups. So, obesity had no major impact on the clinical
onset and course of diabetes hereby. At the time of diag-
nosis, all patients were being treated with oral hypoglyc-
emic agents; however, 13.3% (4/30) of the patients were
shifted to insulin therapy during the investigation.
According to this point and the laboratory results; fasting
blood glucose, fasting serum insulin HbA1c, and being
well controlled patients, sensitivity of oral hypoglycemic
agents in our MODY patients is noticeable.
Mutation Identification
Comparison of sequencing results to reference gene
sequence revealed a G→A substitution at codon 255
resulting in a Val (GTG) → Met (ATG) replacement (figure
1). This known mutation was identified in 8/30 (26.6%)
of patients with MODY and 3/21 (14.2%) of relatives. No
mutation was detected in healthy controls. The mean age
of the patients at the time of diagnosis was 24 (12-30),
whereas, these values were 21.5 (14-26) and 16 (12-19) in
8 cases with Val/Met255 mutation in patients group and
3 individuals with mutation in relatives, respectively.
Discussion
HNF4α mutations have been shown to play role in an
autosomal dominant manner in families with an atypical
form of T2D known as maturity onset diabetes of the
young (MODY1) [20,21]. HNF4α's role in MODY origi-
nates from its function as a β cell transcription factor that
influences glucose induced insulin secretion [22]. The
clinical features of the HNF4α phenotype as a subtype of
MODY can overlap with type 1 diabetes. Occasionally,
MODY patients may be misdiagnosed as having type 1
diabetes because they present with polydipsia, polyuria,
and weight loss in their late teens or early 20s. In contrast
to MODY, type 2 diabetes usually affects people between
age 40 and 60 years, but an increasing number of patients
are being diagnosed earlier, even in childhood. These
patients are frequently obese and require insulin therapy.
Approximately equal numbers of patients with MODY
and T2D report a parent with diabetes and more than one
out of three MODY patients can not be distinguished
from those with T2D using traditional diagnostic criteria
of age of onset and family history alone [23]. Both MODY
and T2D patients, have reduced insulin sensitivity as a
Table 3: Comparison of clinical characteristics between affected members, unaffected members of families with Maturity Onset 
Diabetes of the Young (MODY) and control subjects
Affected Members Unaffected Members Control Subjects
Samples(n) 30 21 50
Male/Female 8/22 11/10 20/30
Age at Diagnosis(years) 24 ± 6 -------- --------
Age at Examination(years) 36 ± 5 56 ± 7 41 ± 6
BMI(kg/m2) 26.8 ± 9.2 25.2 ± 5.3 27.1 ± 4.2
Fasting Blood Glucose(mg/dl) 136 ± 62 -------- --------
Fasting Serum Insulin(μU/ml) 14.2 ± 5.4 -------- --------
HbA1C(%) 6.8 ± 2.1 -------- --------Cardiovascular Diabetology 2009, 8:63 http://www.cardiab.com/content/8/1/63
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result of pancreatic β cell dysfunction [24]. So, MODY
should be suspected in young onset apparent T2D cases
when there is no obesity or feature of metabolic syn-
drome. In the case of encountering a patient with some
manifestations of type 1 diabetes and some features of
T2D, in addition to probable clinical diagnosis of MODY,
genetic investigation of identified mutations could let to
better diagnosis. This helps to predict the clinical course of
disease and will influence the management. Finding
mutations associated with MODY in probands has impli-
cations for other family members, particularly, identifica-
tion of asymptomatic carriers that may be beneficial for
earlier diagnosis and treatment in order to avoid compli-
cations. One of the genes to be investigated is HNF4α as a
known cause of MODY1. The current study indicates the
presence of Val/Met255 mutation in almost one forth of
Iranian MODY. In one of the twelve families took part in
this study, 3 individuals developed Val/Met255 mutation
that were all under the age of 25 (12, 17 and 19 years old).
Respecting the occurrence of this mutation in our MODY
patients and probable development of these 3 members
of this family to MODY, in future cases similar to these
conditions, detection of this mutation may help the ear-
lier diagnosis.
Approximately 5-10% of T2D cases are MODY. But Muta-
tions in HNF4α (MODY1) are less frequent and may
account for 2-5% of subjects with MODY [8,25,26]. Only
26 families worldwide have been diagnosed with MODY1
[9,27], although, we found HNF4α mutation (Val/
Met255) in 3 families of our study group. This substitu-
tion changes an amino acid sequence of the HNF4α pro-
tein. In this study, none of the Val/Met255 carriers have
overt hepatic, renal or gastrointestinal dysfunction. So, we
believe this mutation might have an effect on the pancre-
atic beta cell function contributing to the development of
MODY.
In summary, Val/Met255 mutation in the HNF4α gene
was identified in about one fourth of Iranian families
affected with MODY. Therefore, the detection of this
mutation in an Iranian patient with probable MODY pro-
vides a strong support in the definite diagnosis. Although,
we plan to investigate our patients and their family mem-
bers to detect the common mutations of other subtypes of
MODY in the future studies.
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